ANI Pharmaceuticals Croissance future
Future contrôle des critères 4/6
ANI Pharmaceuticals devrait augmenter ses bénéfices et son chiffre d'affaires de 30.4% et de 10% par an respectivement. Le BPA devrait croître de de 12.7% par an. Le rendement des capitaux propres devrait être 25.6% dans 3 ans.
Informations clés
30.4%
Taux de croissance des bénéfices
12.69%
Taux de croissance du BPA
| Pharmaceuticals croissance des bénéfices | 14.5% |
| Taux de croissance des recettes | 10.0% |
| Rendement futur des capitaux propres | 25.64% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 11 May 2026 |
Mises à jour récentes de la croissance future
Recent updates
Mise à jour du récit • May 13
ANIP: Higher Margin Outlook Will Support Bullish Case Over Coming Years
Analysts have maintained their $90.00 price target on ANI Pharmaceuticals, citing updated assumptions around slightly different revenue growth, a higher profit margin, and a lower future P/E as the main factors supporting the unchanged view. What's in the News Raised full year 2026 revenue guidance to a range of US$1.08b to US$1.14b, compared with prior guidance of US$1.055b to US$1.115b (company guidance).Mise à jour du récit • Apr 24
ANIP: 2026 Revenue Guidance And New Launches Will Support Upside Potential
Analysts have kept their $90.00 price target for ANI Pharmaceuticals unchanged, citing relatively steady assumptions for revenue growth, profit margins, and future P/E as the basis for this view. What's in the News Launched Pimozide Tablets 1 mg and 2 mg, a generic version of Orap, with U.S. annual sales for the category of about US$3.1 million based on February 2026 IQVIA data (Key Developments).Seeking Alpha • Apr 10
ANI Pharmaceuticals Looks Undervalued As Cortrophin Drives Rare Disease Growth
Summary ANI Pharmaceuticals continues shifting toward rare diseases, with management projecting that this segment will represent 60% of its 2026 revenues. However, their generics remain a reliable cash engine. These products grew 28% in 2025 and reached $384 million in revenues. This way, ANIP has been able to fund its expansion into rare diseases, with Cortrophin as its flagship asset in this category. Cortrophin has an extremely promising multi-indication potential, as well as plans for a prefilled syringe launch supported by another Phase 4 gout study. On balance, I think ANIP’s valuation seems exceedingly cheap relative to its stable revenue growth and positive cash flows, which is why I rate the stock a “Buy”. Read the full article on Seeking AlphaMise à jour du récit • Apr 08
ANIP: 2026 Revenue Guidance Will Test Confidence In Margin Assumptions
Analysts lifted their price target on ANI Pharmaceuticals by $9, reflecting updated expectations around revenue growth, profit margin, and future P/E assumptions highlighted in recent Street research. Analyst Commentary While the updated target reflects renewed confidence in revenue and margin assumptions, bearish analysts are still flagging several areas where expectations may be running ahead of what the company can reasonably deliver.
Mise à jour du récit • Mar 25
ANIP: Higher 2026 Guidance And Margin Outlook Will Support Stronger Earnings Power
Analysts have raised their price target on ANI Pharmaceuticals by $9 to $110.63, citing updated expectations for revenue growth, profit margins, and a lower future P/E assumption. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as better aligned with updated expectations for revenue and margin performance, which they factor into their cash flow and earnings models.Mise à jour du récit • Mar 11
ANIP: Higher 2026 Guidance Will Test Assumed Margin Expansion
Analysts have lifted their price target on ANI Pharmaceuticals by $9, citing updated assumptions for revenue growth, profit margins, and a revised future P/E multiple that together reshape their view of the stock's long term earnings power. Analyst Commentary While the higher price target reflects updated assumptions, bearish analysts are also flagging several risks that could limit upside if execution or market conditions do not line up with those assumptions.Mise à jour du récit • Feb 24
ANIP: Higher 2026 Revenue Guidance Will Support Richer Forward P/E Multiple
Analysts have lifted their price target on ANI Pharmaceuticals by $9, reflecting updated assumptions for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Bullish Takeaways Bullish analysts view the US$9 price target increase as a sign that updated revenue assumptions support a higher valuation multiple on forward earnings.Mise à jour du récit • Feb 10
ANIP: Higher 2026 Revenue Outlook And Refined P/E Framework Will Support Upside
Analysts have raised their price target on ANI Pharmaceuticals by about $1 to $110.50, citing updated views on revenue growth, profit margins, discount rate, and future P/E assumptions reflected in recent research. Analyst Commentary Bullish Takeaways Bullish analysts see the higher US$110.50 target as better aligned with updated assumptions on revenue and margins, suggesting the stock now reflects their latest fundamental work more closely.Mise à jour du récit • Jan 26
ANIP: Future Outlook Will Balance Higher Guidance Expectations And Execution Risks
Analysts have raised their price target on ANI Pharmaceuticals by $9, citing updated expectations for revenue growth, profit margins, and a slightly lower future P/E as key drivers of their revised view. Analyst Commentary While the higher price target signals some confidence around updated revenue and margin expectations, bearish analysts are still flagging areas where the risk and reward profile may feel less attractive for new money.Mise à jour du récit • Jan 12
ANIP: Raised Revenue Outlook And Pipeline Update Will Support Further Upside
Narrative Update on ANI Pharmaceuticals Analysts have trimmed their price target on ANI Pharmaceuticals to about $109.25 from roughly $109.88, citing updated assumptions around slightly higher revenue growth expectations, a modestly lower profit margin outlook, and a small adjustment in the forward P/E multiple. What’s in the News ANI Pharmaceuticals raised its full year 2025 net revenue guidance to a range of US$854 million to US$873 million, compared with prior guidance of US$818 million to US$843 million (Key Developments).Mise à jour du récit • Dec 26
ANIP: Future Outlook Will Balance Corticotropin Momentum And Concentration Risks
Analysts have raised their price target on ANI Pharmaceuticals to $90 from $77, citing continued momentum from Cortrophin Gel, record Q2 sales of $82M, and a 20% full year guidance increase that supports expectations for sustained growth. Analyst Commentary Bearish analysts acknowledge that the higher $90 price target reflects recent strength, but they emphasize that the rating remains at Hold, signaling caution around near term upside.Mise à jour du récit • Dec 12
ANIP: Future Outlook Balances Corticotropin Market Expansion And Competitive Uncertainties
Analysts have lifted their fair value estimate for ANI Pharmaceuticals to $90 from $77 per share as they factor in stronger than expected Cortrophin Gel momentum, higher sales visibility, and an expanding addressable market, despite slightly more conservative growth and margin assumptions. Analyst Commentary Recent Street research reflects a growing divide between optimistic expectations for Cortrophin Gel and a more cautious stance from bearish analysts who question the durability of current momentum and the stock's valuation profile.Mise à jour du récit • Nov 26
ANIP: Continued Momentum Will Drive Upside as Market Opportunities Expand
Analysts have raised their price targets for ANI Pharmaceuticals, with increases ranging from $13 to $28 per share. They cite strong Cortrophin Gel sales momentum, expanded market opportunities, and resilient fundamentals as key factors driving the company’s continued growth outlook.Mise à jour du récit • Nov 10
ANIP: Sustained Revenue Expansion Will Drive Momentum Amid Increasing Market Opportunities
Analysts have increased their average price target for ANI Pharmaceuticals from $105 to approximately $109.88, citing robust Cortrophin Gel performance, expanded market opportunities, and a strengthened revenue outlook. Analyst Commentary Industry analysts are closely monitoring ANI Pharmaceuticals following a series of price target increases.Mise à jour du récit • Sep 25
Expanding ACTH Potential And Rare Disease Markets Will Evolve
ANI Pharmaceuticals’ price target was raised to $105.00 as analysts cite robust Cortrophin Gel prescription trends, a significantly expanded addressable market, and outstanding Q2 revenue growth. Analyst Commentary Bullish analysts highlight that Cortrophin Gel prescription data is consistently surpassing forecasts, indicating stronger-than-expected demand.Mise à jour du récit • Aug 10
Expanding ACTH Potential And Rare Disease Markets Will Evolve
Despite a meaningful reduction in consensus revenue growth forecasts, ANI Pharmaceuticals’ future P/E multiple has declined, improving perceived value and contributing to an upward revision of the consensus analyst price target from $81.38 to $85.75. What's in the News ANI Pharmaceuticals raised 2025 earnings guidance to $818–$843 million from prior $768–$793 million.Article d’analyse • Aug 10
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Surges 25% Yet Its Low P/S Is No Reason For Excitement
NasdaqGM:ANIP 1 Year Share Price vs Fair Value Explore ANI Pharmaceuticals's Fair Values from the Community and select...Article d’analyse • Jun 21
Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Article d’analyse • May 16
We Think Shareholders Will Probably Be Generous With ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) CEO Compensation
Key Insights ANI Pharmaceuticals' Annual General Meeting to take place on 22nd of May Total pay for CEO Nikhil Lalwani...Article d’analyse • Mar 28
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Fly 25% But Investors Aren't Buying For Growth
ANI Pharmaceuticals, Inc. ( NASDAQ:ANIP ) shareholders have had their patience rewarded with a 25% share price jump in...Article d’analyse • Feb 25
Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Feb 11
ANI Pharmaceuticals: More Than Just A Generics Company
Summary ANI Pharmaceuticals offers an asymmetric opportunity in small-cap pharma, with a niche in generics, rare disease treatments, and contract manufacturing. Despite cash burn concerns, ANI's revenue growth, strategic moves, and overlooked royalty streams indicate long-term value creation. ANI's rare disease asset, Purified Cortrophin Gel, and generics pipeline, including Prucalopride, position it for significant revenue growth and market re-rating. The company's debt restructuring and diversified revenue streams enhance financial stability, making it a potential buyout target in the specialty pharma sector. Read the full article on Seeking AlphaArticle d’analyse • Dec 18
ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Prospects Need A Boost To Lift Shares
You may think that with a price-to-sales (or "P/S") ratio of 2x ANI Pharmaceuticals, Inc. ( NASDAQ:ANIP ) is a stock...Article d’analyse • Nov 09
Here's Why ANI Pharmaceuticals (NASDAQ:ANIP) Can Manage Its Debt Responsibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Seeking Alpha • Nov 02
ANI Pharmaceuticals Is Acting Like It Is Being Acquired
Summary Several actions or omissions by ANIP is consistent with them being acquired and being restricted in what they can disclose. Offer could exceed $8 billion plus sales based CVRs. Offer likely contingent on FDA approval of NDA filed in Q3 2023 for undisclosed drug filed by ANIP but application appears to be financed by undisclosed partner. Read the full article on Seeking AlphaSeeking Alpha • Oct 11
ANI Pharmaceuticals: A Rare GARP Stock In An Overbought Market
Summary Today, we revisit small biopharma ANI Pharmaceuticals, as it is a GARP stock trading near technical support, with solid growth prospects. The company recently acquired Alimera Sciences for $380 million, boosting its rare disease segment with a couple of durable ophthalmology products. Analyst firms are generally bullish on the company's prospects and the stock trades at 12 times trailing earnings, despite revenue growth in the high teens. An analysis of ANIP follows in the paragraphs below. Read the full article on Seeking Alpha
Nouveau récit • Sep 15
Purified Cortrophin Gel And Strategic Acquisitions Propel Robust Revenue Surge In Rare Disease Sector
Accelerating demand for their lead Rare Disease asset and growth in generics, along with expanding sales efforts, are expected to significantly boost revenues.Article d’analyse • Sep 10
There's No Escaping ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Muted Revenues
ANI Pharmaceuticals, Inc.'s ( NASDAQ:ANIP ) price-to-sales (or "P/S") ratio of 2.2x might make it look like a buy right...Article d’analyse • Aug 14
ANI Pharmaceuticals' (NASDAQ:ANIP) Earnings Are Weaker Than They Seem
ANI Pharmaceuticals, Inc.'s ( NASDAQ:ANIP ) robust earnings report didn't manage to move the market for its stock. Our...Article d’analyse • Aug 08
Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Aug 02
ANI Pharmaceuticals: Tezruly Just Approved, 2 More NDAs Under Review And Alimera Science Acquisition Could Triple Revenue By 2028
Summary ANIP has three 505(b)(2) NDA submissions under FDA review, including oral liquid terazosin, female testosterone drug, and oral liquid hydrochlorothiazide. Potential peak sales for Tezruly and hydrochlorothiazide in the US could exceed $500 million, while the female testosterone drug could generate $290 million in royalties. ANIP's revenue could reach $1.41 billion in sales and $290 million in royalties by 2028, with significant growth potential. Read the full article on Seeking AlphaArticle d’analyse • Jun 10
Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price
There wouldn't be many who think ANI Pharmaceuticals, Inc.'s ( NASDAQ:ANIP ) price-to-sales (or "P/S") ratio of 2.5x is...Seeking Alpha • Jun 10
ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked
Summary ANIP's potential royalty revenue from two upcoming drug applications could generate $415 million annually, not reflected in the current share price. ANI Pharmaceuticals' legal action against CG Oncology could result in royalties for Cretostimogene, potentially adding $125 million per year. The Company's female testosterone drug could generate royalties of $290 million per year, with potential for additional indications and international sales. Read the full article on Seeking AlphaPrévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2028 | 1,359 | 262 | 287 | 300 | 5 |
| 12/31/2027 | 1,249 | 172 | 231 | 246 | 7 |
| 12/31/2026 | 1,123 | 121 | 198 | 208 | 7 |
| 3/31/2026 | 924 | 84 | 183 | 209 | N/A |
| 12/31/2025 | 883 | 70 | 151 | 185 | N/A |
| 9/30/2025 | 827 | 34 | 135 | 171 | N/A |
| 6/30/2025 | 747 | -14 | 104 | 139 | N/A |
| 3/31/2025 | 674 | -22 | 49 | 81 | N/A |
| 12/31/2024 | 614 | -20 | 47 | 64 | N/A |
| 9/30/2024 | 555 | -9 | 74 | 93 | N/A |
| 6/30/2024 | 539 | 24 | 94 | 113 | N/A |
| 3/31/2024 | 517 | 31 | 95 | 116 | N/A |
| 12/31/2023 | 487 | 15 | 100 | 119 | N/A |
| 9/30/2023 | 449 | 10 | 53 | 70 | N/A |
| 6/30/2023 | 401 | -8 | 19 | 41 | N/A |
| 3/31/2023 | 359 | -28 | -7 | 9 | N/A |
| 12/31/2022 | 316 | -50 | -48 | -31 | N/A |
| 9/30/2022 | 283 | -69 | -53 | -39 | N/A |
| 6/30/2022 | 251 | -65 | -52 | -48 | N/A |
| 3/31/2022 | 226 | -63 | -61 | -36 | N/A |
| 12/31/2021 | 216 | -43 | -20 | 3 | N/A |
| 9/30/2021 | 212 | -22 | -16 | 10 | N/A |
| 6/30/2021 | 213 | -17 | -17 | 14 | N/A |
| 3/31/2021 | 213 | -15 | 23 | 34 | N/A |
| 12/31/2020 | 208 | -23 | -53 | 15 | N/A |
| 9/30/2020 | 199 | -24 | -42 | 26 | N/A |
| 6/30/2020 | 198 | -20 | -15 | 49 | N/A |
| 3/31/2020 | 203 | -1 | -32 | 33 | N/A |
| 12/31/2019 | 207 | 6 | N/A | 46 | N/A |
| 9/30/2019 | 216 | 16 | N/A | 68 | N/A |
| 6/30/2019 | 215 | 17 | N/A | 55 | N/A |
| 3/31/2019 | 208 | 14 | N/A | 58 | N/A |
| 12/31/2018 | 202 | 15 | N/A | 67 | N/A |
| 9/30/2018 | 192 | 0 | N/A | 56 | N/A |
| 6/30/2018 | 189 | 0 | N/A | 64 | N/A |
| 3/31/2018 | 187 | 0 | N/A | 56 | N/A |
| 12/31/2017 | 177 | -1 | N/A | 39 | N/A |
| 9/30/2017 | 168 | 7 | N/A | 36 | N/A |
| 6/30/2017 | 158 | 5 | N/A | 20 | N/A |
| 3/31/2017 | 145 | 4 | N/A | 23 | N/A |
| 12/31/2016 | 129 | 4 | N/A | 27 | N/A |
| 9/30/2016 | 108 | 8 | N/A | 20 | N/A |
| 6/30/2016 | 90 | 10 | N/A | 29 | N/A |
| 3/31/2016 | 78 | 12 | N/A | 27 | N/A |
| 12/31/2015 | 76 | 15 | N/A | 17 | N/A |
| 9/30/2015 | 79 | 33 | N/A | 23 | N/A |
| 6/30/2015 | 77 | 35 | N/A | 17 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de ANIP ( 30.4% par an) est supérieure au taux d'épargne ( 3.5% ).
Bénéfices vs marché: Les bénéfices de ANIP ( 30.4% par an) devraient croître plus rapidement que le marché US ( 16.8% par an).
Croissance élevée des bénéfices: Les bénéfices de ANIP devraient augmenter de manière significative au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de ANIP ( 10% par an) devrait croître plus lentement que le marché de US ( 11.7% par an).
Croissance élevée des revenus: Le chiffre d'affaires de ANIP ( 10% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de ANIP devrait être élevé dans 3 ans ( 25.6 %)
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/26 22:24 |
| Cours de l'action en fin de journée | 2026/05/26 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
ANI Pharmaceuticals, Inc. est couverte par 16 analystes. 7 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Glen Santangelo | Barclays |
| Dewey Steadman | Canaccord Genuity |
| Timothy Chiang | Capital One Securities, Inc. |